StonvexLoading…
StonvexStonvexStonvexCore line items from CTAS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-02-28 | Q4 2025 2025-11-30 | Q3 2025 2025-08-31 | Annual 2025 2025-05-31 |
|---|---|---|---|---|
Revenue | $8.36B | $5.52B | $2.72B | $10.34B |
Operating Income | $1.93B | $1.27B | $617.86M | $2.36B |
Net Income | $1.49B | $495.34M | $491.14M | $1.81B |
EPS (Diluted) | $3.65 | $2.41 | $1.20 | $4.40 |
Total Assets | $10.23B | $10.13B | $9.84B | $9.83B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $183.20M | $200.84M | $138.14M | $263.97M |
Free Cash Flow OCF − CapEx | $1.27B | $737.50M | $312.52M | $1.76B |
Shares Outstanding | 400.01M | 399.86M | 402.95M | 402.95M |